Literature DB >> 29280492

Unexpected prominent tension pneumosella five years after endoscopic endonasal transsphenoidal surgery.

Tatsuma Matsuda1, Kentaro Horiguchi1, Yoshinori Higuchi1, Toyoyuki Hanazawa2, Yoshitaka Okamoto2, Yasuo Iwadate1.   

Abstract

Tension pneumosella (TP) is a rare entity reported as the invagination of the sphenoid sinus mucosa into the skull base after endonasal transsphenoidal surgery. Few studies have reported on TP, and in these studies, invagination is confined to either the intrasellar or suprasellar area. We encountered a case of unexpected prominent TP toward the intracranial space 5 years after endoscopic endonasal transsphenoidal surgery (EETS) for a nonfunctioning pituitary adenoma. In addition, we present a hypothesis of the underlying mechanism by a pressure gradient change between the extracranial and intracranial space in TP formation. For repair, a pedicled nasal septal flap was fabricated from the remaining part of the septal mucosa, and a pedicled inferior turbinate flap was created. Moreover, the nasal septal cartilage was used as a rigid support for reconstruction, which was useful for preventing TP recurrence. This is the first report of an unexpected prominent TP after EETS. It is important for otorhinolaryngologists and neurosurgeons to be aware of the possibility of TP following EETS. Laryngoscope, 1798-1801, 2018.
© 2017 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Tension pneumosella; endoscopic endonasal transsphenoidal surgery; pituitary adenoma; sellar reconstruction

Mesh:

Year:  2017        PMID: 29280492     DOI: 10.1002/lary.27060

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  1 in total

1.  Tension Pneumocephalus from Endoscopic Endonasal Surgery: A Case Series and Literature Review.

Authors:  Wanpeng Li; Quan Liu; Hanyu Lu; Huan Wang; Huankang Zhang; Li Hu; Xicai Sun; Yurong Gu; Houyong Li; Weidong Zhao; Dehui Wang
Journal:  Ther Clin Risk Manag       Date:  2020-06-19       Impact factor: 2.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.